Arrowhead and Madrigal sign global licence for MASH RNAi therapy

📅 06/05/2026 09:29 📰 pharmaceutical_technology 👁️ 3 lectures 🌍 Royaume-Uni 📂 Santé

Madrigal Pharmaceuticals has signed an exclusive global licence agreement for Arrowhead's RNAi therapeutic therapy ARO-PNPLA3 to treat MASH.